WHO Raises Concern Over Critical Scarcity of Obesity Injections

Less than one in 10 people who could benefit from weight-loss injections like Wegovy have access to them, states the WHO as it releases its inaugural guidance on the drugs.

With more than one billion individuals worldwide currently obese, it is calling for more widespread and fairer availability to this class of drugs.

Based on estimates, over two billion could be obese by 2030 unless action is taken.

"The new guidelines recognises that excess weight is a lifelong illness that can be treated with holistic and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are major hurdles to universal access to the injections that can aid individuals in losing substantial body mass, notes the agency.

Skinny Jab Supply Crisis

Even under the present best projected case, the manufacturing of these medications could only cover approximately 100 million people – under 10% of eligible patients, as stated by the health organization.

The advice urges nations and manufacturers to expand access, through approaches including licensing agreements.

A patent on the active ingredient – the main component of a leading brand – is due to expire in a number of nations in 2026.

The Way Obesity Jabs Function

GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so users reduce food intake.

Individuals usually start to lose weight after several weeks of starting on the weekly injections.

Research suggests users may put most of the weight back on after a year of halting the treatment, when their normal appetite return.

To be carrying excess weight elevates your chance for experiencing health problems, including diabetes, heart disease, brain attack, and some cancers.

Obesity concerns individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.